Best Grants for Computers for Nonprofits in Wyoming

The CAO Legislative Crisis Grant, funded by the National Education Association Staff Organization, is designed to support affiliates in creating and refining student-centered initiatives. Grants can be utilized for contract campaigns, new program development, or enhancing existing practices to improve sustainable learning conditions. This opportunity is exclusive to affiliates, ensuring a focused approach to advocacy and collective bargaining efforts that benefit students.

The National Cancer Institute (NCI) invites applications for the validation of molecular, cellular, and imaging markers for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation phases, emphasizing multi-disciplinary collaboration. The UH2 phase focuses on analytical validation, while the UH3 phase extends to clinical validation using well-annotated biospecimens. Proposals should justify the relevance of assays for clinical use and may include harmonization efforts across laboratories.

The Goodridge Brothers Scholarship, offered by the Saginaw Community Foundation, supports residents of Saginaw County pursuing careers in technical education, such as welding or auto mechanics. This initiative recognizes the growing demand for skilled tradespeople and aims to alleviate financial barriers for students. Scholarships typically range from $500 to $4,000, promoting educational opportunities in urban and regional planning and enhancing the community's workforce capabilities.

American Headache Society

The American Headache Society (AHS) is a professional society of healthcare providers dedicated to the study and treatment of headache and face pain. The Mission of the AHS is to improve the lives of people impacted by migraine and other headache disorders. AHS advocates for those impacted by headache and the headache field, to meet our core objectives. AHS provides educational courses, scientific meetings, a journal, research support, career development opportunities, Special Interest Groups, advocacy training, and a professional community. The AHS strives to meet its objectives while fostering an inclusive sense of belonging and community.

Headache & Migraine Competitive Grant Program

The Headache & Migraine Competitive Grant Program stands at the forefront of advancing headache medicine by funding groundbreaking quality improvement initiatives. This highly competitive grant program, offered through the collaboration between the American Headache Society and Pfizer, supports projects that have the potential to reshape the field by creating widely applicable tools and driving measurable improvements in patient care. 

Adult Population  RFP (Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache Disorder)

Seeking projects that drive meaningful impact in headache care through advancements in safety, clinical effectiveness, timely diagnosis, and equitable, patient-centered treatment. Submissions should feature bold, practical solutions in primary care and non-headache specialty settings, supporting adult populations with scalable, real-world innovations. 

The Shubert Foundation provides unrestricted grants to not-for-profit professional theatre and dance companies in the U.S. Its focus is on organizations with a proven track record in artistic and administrative excellence. Eligible applicants must have a minimum annual budget of $150,000 and demonstrate financial stability, strong community engagement, and the ability to generate income. The foundation does not fund individuals, project-specific requests, or organizations without 501(c)(3) status.

The ASTR Jessica Berson Dance Research Assistance Fund Grant aims to support contingent faculty engaged in dance-based scholarship within theatre. This initiative acknowledges the critical role of non-tenure track faculty and provides them with a $1000 honorarium, conference registration, and a one-year ASTR membership. The grant encourages research and attendance at the annual ASTR conference, ensuring broader access to resources and professional opportunities for those who often lack institutional support.

The CLRA Research Grant Program, led by the Children’s Leukemia Research Association, focuses on funding innovative research aimed at uncovering the causes of leukemia and improving treatment options. Grants totaling $30,000 are awarded to U.S.-based researchers, with the intention of advancing scientific understanding and ultimately finding a cure. The program has made significant contributions to the high cure rates for childhood leukemia, showcasing the importance of continued research in this field.

The Guy Bradley Award, established in 1988 by the National Fish and Wildlife Foundation (NFWF), honors individuals who have made significant contributions to wildlife law enforcement. Named after the first wildlife officer killed in the line of duty, this award recognizes the vital role of law enforcement agents in wildlife conservation. Eligible candidates include current and retired personnel from state and federal agencies who have demonstrated exemplary dedication to protecting wildlife and advancing enforcement goals.

The NIMH Career Transition Award (K22) supports tenure-track intramural investigators at NIMH in their transition to independent research faculty positions. This program aims to foster innovative research in mental health, encouraging applicants with a strong record of research excellence. Key deadlines for applications vary, including those for standard and renewal submissions, emphasizing the importance of timely applications to secure funding and advance mental health research initiatives.

The ASTR Selma Jeanne Cohen Conference Presentation Award supports scholars participating in plenary or working sessions at the ASTR conference. This award encourages exploration of the intersections between theatre and dance, providing funds for travel and hotel expenses. Eligible applicants include graduate students, independent scholars, and faculty members accepted to present at the 2025 conference. The award offers a $1000 honorarium and complimentary registration, promoting active engagement in ASTR's community.

The FY26 Autism Research Program Clinical Trial Award aims to rapidly implement clinical trials that significantly impact autism treatment and management. Projects may range from small proof-of-concept trials to large-scale studies assessing efficacy in relevant populations. Applications are encouraged to partner experienced and early-career investigators and must include community collaborations to enhance research impact. At least one community partner is required to provide ongoing consultation throughout the project.

The Music and Entertainment Industry Educators Association (MEIEA) offers Student Enrichment Grants to support educational activities in the music and entertainment fields. Grants of up to $1,000 are available for accredited institutions that are MEIEA members. Eligible projects include workshops, guest speakers, and community service initiatives. Special consideration is given to first-time applicants and projects promoting diversity and inclusion, aiming to enrich student experiences and foster greater engagement within the industry.

This initiative aims to support research interventions targeting disparities in liver diseases and liver cancer among underserved populations in the U.S. It encourages innovative approaches to reduce health inequities and improve health outcomes. The funding opportunity is available through various deadlines for both standard and renewal applications, promoting multi-level strategies to address these critical health issues effectively.

The FY26 Autism Research Program's Idea Development Award from the US DOD aims to support groundbreaking research that improves outcomes for Autistic individuals. This award encourages innovative, high-risk projects that can lead to significant advancements in autism research. Applications must address specific areas of interest or justify the importance of the research problem. A unique Partnering Principal Investigator option allows two researchers to collaborate on a single project, enhancing the potential for impactful discoveries.

The Student Enrichment Grants: Level II Awards, offered by the Music & Entertainment Industry Educators Association (MEIEA), provide up to $500 for non-institutional members to support student activities in music and entertainment. Eligible applicants include faculty in good standing, promoting diverse initiatives. Grants can fund workshops, guest speakers, and community projects, with a focus on enhancing student education and engagement in the industry. Special consideration is given to first-time applicants and impactful projects.

The NCAA Jim McKay Graduate Scholarship honors the legacy of journalist Jim McKay by awarding a one-time $10,000 scholarship to one male and one female student-athlete annually. Eligible candidates must have a minimum GPA of 3.5, demonstrate integrity, and show interest in sports communication. There is no limit to the number of nominations from institutions, highlighting the NCAA's commitment to supporting student-athletes in their academic and professional pursuits.

The NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33) invites research proposals for early phase clinical trials of natural products, including botanicals and dietary supplements, emphasizing scientific validity for further testing. Applicants may receive up to three years of funding for pharmacokinetics and bioavailability studies, with potential for an additional three years to evaluate clinical outcomes. This initiative aims to optimize natural product delivery through innovative study designs.

The NCCIH Natural Product Early Phase Clinical Trial Award supports innovative clinical trials of natural products, such as botanicals and dietary supplements, with a strong scientific basis. Applications are encouraged to explore optimal delivery methods and combinations with other treatments. Funding is available for up to three years to assess the impact on target engagement and clinical outcomes, aiming to translate basic science findings into practical clinical applications.

The NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required) grant invites applications for mid-phase clinical trials focusing on natural products such as botanicals and dietary supplements. It aims to advance scientific knowledge by determining optimal dosing and patient responses. Applicants must provide preliminary data demonstrating bioavailability and measurable impacts on target engagement. This initiative will not support efficacy trials for cancer treatments and encourages early contact with NCCIH scientific contacts.

The FY26 Autism Research Program Career Development Award aims to support early-career investigators in conducting innovative research that can significantly impact autism. It encourages applications addressing specific areas of interest and mandates community collaboration for projects involving pilot clinical trials. Proposals must include partnerships with community members for effective planning and implementation, ensuring that the research is grounded in the needs of the autism community.

This grant mechanism will focus on furthering the development of novel strategies towards improving the treatment of Small Cell Lung Cancer (SCLC). Work supported through this mechanism will address important areas of need across the entire care continuum and have the immediate potential to increase survivorship. It is expected that correlative translational research will be proposed that will enhance the understanding of SCLC.The overarching theme of the proposals should be centered around understanding the biology of SCLC and developing strategies toward improving outcomes for patients with SCLC. We will encourage applications on a wide variety of topics related to SCLC, including but not limited to the following:

• Advanced Screening and Diagnostic Technologies
  • Utilize liquid biopsies and circulating tumor DNA (ctDNA) to enhance early detection and monitoring of SCLC, providing non-invasive diagnostic and prognostic solutions
  • Investigate the clinical utility of blood-based biomarkers for improving SCLC diagnosis, monitoring treatment response, and predicting outcomes
  • Leverage artificial intelligence for the early detection of SCLC

• Disease Progression and Acquired Resistance
  • Study of molecular + clinical characteristics of rapid progressors vs. long-term responders in SCLC to tailor personalized treatment approaches
  • Leverage radiomics to identify predictive or prognostic factors such as treatment response, risk of pneumonitis, and likelihood of brain metastases
  • Investigate the underlying mechanisms of primary and acquired resistance to chemotherapy and immunotherapy in SCLC
  • Identify and validate biomarkers indicative of disease progression and/or therapeutic resistance

• Biomarkers and Immuno-Oncology
  • Identify and validate biomarkers that can predict greater responses to immunotherapy treatments in SCLC, enhancing patient selection and treatment efficacy

• Biospecimen-based research
  • Leverage real-world patient tissue and/or blood samples to enable:
    • Longitudinal studies of SCLC progression from limited-stage to extensive-stage disease
    • Investigation of tumor and microenvironmental changes before, during, and after treatment to understand the evolution of resistance
  • Develop a centralized infrastructure for biospecimen collection, with standardized protocols and accessible repositories to facilitate broad research collaboration

These awards provide a maximum of $500,000 in funding over a period of three years.

The Craft Archive Fellowship supports archival research on underrepresented craft histories in the U.S., including feminist, queer, Black, Indigenous, and other marginalized communities. It offers a $5,000 stipend for scholars and artists to conduct research in chosen archives, encouraging innovative approaches. Participants will present their findings in a virtual program, and their work will be published in Hyperallergic, broadening accessibility and awareness of vital craft research.

The Retina Society, Inc.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina. The Retina Society began as an outgrowth of alumni meetings of Retina Associates, a retina practice founded in Boston in 1951 by Charles L. Schepens. Dr. Schepens is credited with establishing retina surgery as a sub-specialty.  

Our mission is to reduce worldwide visual disability and blindness by promoting the education and professional interaction of vitreoretinal specialists, providing optimal care for patients with vitreoretinal diseases, and encouraging, through clinical and basic research, the discovery and development of new means to further patient care.

Retina Society Underrepresented in Medicine (RESOURCE) Mentoring Program

The Retina Society Underrepresented in Medicine (RESOURCE) Mentoring Program was created to engage and interest ophthalmology residents from underrepresented populations* in research and in pursuing careers in the retina subspecialty through dedicated mentoring exposure. The program will pair ophthalmology residents from underrepresented backgrounds with Retina Society mentors, with the goal of providing the residents with research and career mentorship.

*The American Association of Medical Colleges definition of underrepresented in medicine is: "Underrepresented in medicine means those racial and ethnic populations that are underrepresented in the medical profession relative to their numbers in the general population." We define the following groups as underrepresented: Black (African American or African), Latino/Hispanic, American Indian, Alaska Native, Native Hawaiian or Pacific Islander. We will also be considering applicants from LGBTQIA+ and socioeconomically underprivileged backgrounds.

Mentors will work with their designated mentees on research projects that will be presented at the Retina Society Annual Meeting in 2027 and submitted for publication consideration. Mentors and mentees will be acknowledged at the Retina Society Annual Meeting.

Myasthenia Gravis Rare Disease Network (MGNet)

The Myasthenia Gravis Rare Disease Network (MGNet) is a consortium of academic medical centers partnering with the Myasthenia Gravis Foundation of America and Conquer MG as well as collaborators in other research groups and industry. We are working together to enhance therapeutic development for this rare disease.

Diseases Studied

Myasthenia Gravis (MG) and its subtypes:

• Early-onset acetylcholine receptor (AChR) antibody (Ab) positive MG, which primarily affects women
• Late-onset AChR Ab positive MG with a disease bias towards men
• Paraneoplastic thymoma-associated MG
• Muscle specific kinase (MuSK) Ab positive
• AChR/MuSK antibody negative MG

Goals, Mission, & Vision

The goal of MGNet is to advance therapeutic development. To do so we have four specific aims:

• Improve the tools scientists and doctors have for performing clinical trials through rigorous monitoring of patients over time and evaluate better measures of how patients are doing.
• Identify objective measures (biomarkers) to show how the disease is responding to treatment and better predict treatment response or side effects, to improve the design of clinical trials and care of patients in clinical practice.
• Enhance the education of young investigators focusing their careers on rare diseases and specifically MG.
• Improve the awareness of scientists, physicians, and the public regarding the unique needs of patients with MG through training of clinician scientists and engagement of the patient and scientific communities in clinical research and therapeutic development.

Scholar Awards

Objectives

There is a critical need for investigators prepared to conduct clinical and translational research in myasthenia gravis (MG). The MGNet Scholar Program provides individualized training and mentorship in one of two tracks, Clinical Research or Biomarker Development Research.

Award Description

The MGNet Scholar Program provides mentored research training to prepare Scholars for an independent research career in the field of MG. The MGNet Scholar Program is 1 year in duration and selected Scholars receive up to $100,000 to support salary, research costs and didactics with potential for renewal. The program will provide an additional $3,000 to travel to MGNet sites to learn specific skills and/or to scientific meeting(s) to present the results of their research. If available for renewal, the program requires approval after interim report and is contingent on demonstration of adequate progress on the research and career development plan. Indirect costs are not allowed. Scholars are encouraged to transition to NIH (e.g., K award), departmental, or private foundation support for their research and further career development.Research must constitute at least 50% of each Scholar’s professional effort. Each Scholar must form a 2-3-member advisory committee to include a primary mentor, an additional clinician investigator or collaborator, and a MGNet faculty sponsor. The advisory committee will meet with the Scholar at least quarterly to review progress and each Scholar will develop an individual academic career development plan and renew it with the committee at least every 6 months.

Myasthenia Gravis Rare Disease Network (MGNet)

The Myasthenia Gravis Rare Disease Network (MGNet) is a consortium of academic medical centers partnering with the Myasthenia Gravis Foundation of America and Conquer MG as well as collaborators in other research groups and industry. We are working together to enhance therapeutic development for this rare disease.

Diseases Studied

Myasthenia Gravis (MG) and its subtypes:

• Early-onset acetylcholine receptor (AChR) antibody (Ab) positive MG, which primarily affects women
• Late-onset AChR Ab positive MG with a disease bias towards men
• Paraneoplastic thymoma-associated MG
• Muscle specific kinase (MuSK) Ab positive
• AChR/MuSK antibody negative MG

Goals, Mission, & Vision

The goal of MGNet is to advance therapeutic development. To do so we have four specific aims:

• Improve the tools scientists and doctors have for performing clinical trials through rigorous monitoring of patients over time and evaluate better measures of how patients are doing.
• Identify objective measures (biomarkers) to show how the disease is responding to treatment and better predict treatment response or side effects, to improve the design of clinical trials and care of patients in clinical practice.
• Enhance the education of young investigators focusing their careers on rare diseases and specifically MG.
• Improve the awareness of scientists, physicians, and the public regarding the unique needs of patients with MG through training of clinician scientists and engagement of the patient and scientific communities in clinical research and therapeutic development.

Pilot and Feasibility Grants

Objectives

MGNet, a NIH-funded Rare Diseases Clinical Research Consortium (RDCRC) in partnership with the Myasthenia Gravis Foundation of America and Conquer MG, is seeking proposals for highly innovative investigations in early stages of development.

The priorities of the Pilot Grant Program are:

• Identification treatment responsive biomarkers
• Assess clinical measures and improve that enhance clinical trial readiness
• Evaluation of therapeutic interventions for one or more of the five distinct sub-types of MG

Pilot studies must be designed to access the resources of MGNet and focused on clinical and translational research, including fulfilling the definition of clinical and translational research and exclusion of animal studies.

Funding

The MGNet expects to fund up to two grants, each at a level of $75,000 (IDCs will be limited to 10% and included in the $75,000). Projects will be funded for 12 months. Selection among the applications received will be based on the recommendations of a review committee. A grant may be renewed for an additional one year with approval of interim report by the same review process and availability of funds. Demonstration of fulfillment of initial aims and justification for additional funding will be required. The request will be required a minimum of three months prior to the initial funding period completion.

Our Littlest Angels – Callie M. Wilson Memorial Scholarship

The “Our Littlest Angels – Callie M. Wilson Memorial Scholarship” was established in 2011 to assist students interested in the field of Nursing.

Callie Wilson was born on December 20, 1981 and was a patient in the Regional Neonatal Intensive Care Unit (RNICU) at Covenant HealthCare in Saginaw. After 46 days of wonderful care, Callie passed away. Her parents, Byron and Mickey Wilson, along with several of their friends started the Our Littlest Angels Fund in 1982. The fund has raised $1.3 million through its golf tournament and bowl-a-thons for the purchase of specialized equipment for the RNICU.

Covenant HealthCare’s RNICU is truly a live saving service for distressed infants throughout the East-Central Region of Michigan. Several thousands of critically ill newborns have been cared for in this unit since its inception.

The golf tournament and bowling event have now been retired and the remaining funds are being used to establish this scholarship to honor all those associated with the RNICU in Callie’s memory. This scholarship will be awarded to students wishing to enter education in nursing. They must demonstrate strong leadership skills and a passion for infants and nursing.

The NCI Continuing Umbrella of Research Experiences (CURE) Non-Mentored Research Scientist Career Development Award (K22) aims to support postdoctoral fellows from underrepresented backgrounds in transitioning to tenure-track positions. This award provides essential funding for salary and research support for three years, enabling candidates to establish independent biomedical careers. Key deadlines for applications range from February 2025 to October 2027, ensuring ample opportunity for eligible researchers to secure funding for their career development.